Bio-rad laboratories, inc. (BIO)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08
Cash flows from operating activities:
Cash received from customers

2,311,925

2,326,310

2,093,948

2,074,024

1,956,084

2,162,520

2,090,030

2,063,805

2,018,755

1,877,483

1,778,316

1,765,667

Cash paid to suppliers and employees

1,818,575

1,989,685

1,916,119

1,808,687

1,730,062

1,806,526

1,804,028

1,664,491

1,639,848

1,536,935

1,386,382

-1,495,669

Interest paid, net

22,330

22,703

22,224

22,756

20,793

20,793

61,233

46,369

56,859

59,834

38,471

-30,792

Income tax payments, net

45,081

62,414

52,136

38,442

31,715

28,939

71,144

93,697

68,750

55,502

37,749

-49,159

Settlement with the SEC and DOJ relating to the FCPA, including interest

-

-

-

-

-

55,050

0

0

-

-

-

-

Investment proceeds and miscellaneous receipts, net

31,673

26,383

18,392

14,597

11,953

15,671

16,760

12,991

9,686

3,625

10,024

6,374

Excess tax benefits from share-based compensation

-

-

-

1,500

3,610

1,349

2,720

2,889

3,168

2,928

664

-5,050

Proceeds from forward foreign exchange contracts, net

285

7,603

-17,724

-1,164

4,353

7,778

1,471

2,870

-2,919

-3,211

2,520

-5,390

Net cash provided by operating activities

457,900

285,500

104,100

216,100

186,210

273,312

169,136

266,480

262,735

225,909

325,074

191,371

Cash flows from investing activities:
Capital expenditures

98,532

129,825

111,332

141,436

112,000

120,999

106,658

142,869

102,888

88,453

68,044

-

Proceeds from dispositions of property, plant and equipment

129

4,315

86

398

79

225

1,214

6,325

234

1,190

1,249

-

Payments for acquisitions and long-term investments

-

-

-

-

4,356

44,627

72,054

39,443

158,538

89,307

35,990

-53,014

Recovery of (payments for) purchases of intangible assets

-8,818

3

3,795

135

1,372

15,479

700

1,780

436

4,081

9,566

-4,000

Payments for purchases of intangible assets

-

-

-

-

-

-

-

-

-

-

-

-84,809

Payments for purchases of restricted investment

0

0

1,000

350

4,210

0

0

-

-

-

-

-

Payments for purchases of marketable securities and investments

371,450

371,019

282,656

278,071

294,497

205,746

386,714

680,966

509,310

240,286

147,554

-77,800

Proceeds from maturities of marketable securities and investments

226,900

225,295

202,247

143,020

170,823

120,390

276,052

327,052

335,781

203,443

78,727

78,906

Proceeds from sales of marketable securities and investments

104,632

77,029

97,523

76,859

78,664

75,725

289,779

131,295

48,825

4,193

7,746

-

Proceeds from divestiture of a product line

0

6,964

0

0

-

-

-

-

-

-

-

-

Payments for (proceeds from) acquisitions and long-term investment

79,386

-266

76,645

14,165

-

-

-

-

-

-

-

-

Restricted cash

-

-

-

-

-

-

-

-

-

6,422

0

-

Net cash used in investing activities

-208,889

-186,978

-175,572

-213,880

-166,869

-190,511

919

-400,386

-386,332

-216,512

-175,952

-146,107

Cash flows from financing activities:
Net payments on line-of-credit arrangements and notes payable

0

0

-36

37

0

-1,560

48

-191

-3,900

-830

2,303

-1,642

Long-term borrowings

-

-

-

-

-

-

-

-

-

424,633

294,750

1,600

Payments on long-term borrowings

643

2,961

316

303

282

253

300,228

620

226,835

206,706

6,823

-11,589

Payments for credit agreement renewal fees

486

0

0

-

-

524

0

0

242

4,010

2,641

-

Payments of contingent consideration

2,477

2,078

3,681

3,500

2,983

2,374

25,474

0

0

-

-

-

Proceeds from Issuances of common stock for shared-based compensation

13,113

14,133

14,604

11,280

8,236

15,051

11,237

10,611

14,249

12,730

10,286

12,912

Tax payments from net share settlement

8,096

8,862

7,310

0

-

-

-

-

-

-

-

-

Proceeds from reissuances of treasury stock for shared-based compensation, net

3,831

0

0

-

-

-

-

-

-

-

-

-

Payments for purchases of treasury stock

28,000

48,912

2,920

0

0

-

-

101

0

0

-

-

Excess tax benefits from share-based compensation

-

-

-

1,506

3,610

1,349

2,720

2,889

3,168

2,928

664

5,050

Net cash (used in) provided by financing activities

-22,758

-48,680

341

9,020

8,581

11,689

-311,697

12,588

-213,560

228,745

293,933

6,331

Effect of Exchange Rate on Cash and Cash Equivalents

2,237

-655

-1,094

-12,858

16,376

-12,790

9,805

10,475

4,837

18,471

2,359

-8,835

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect

228,487

49,181

-72,188

-1,652

44,298

81,700

-131,837

-110,843

-332,320

256,613

445,414

42,760

Adjustments to reconcile net income to net cash used in operating activities [Abstract]
Excess tax benefits from share-based compensation

-

-

-

1,500

3,610

-

2,720

2,889

3,168

2,928

664

-5,050

Capital lease obligation for facilities

-

-

-

-

-

-

-

-

-

-

-

9,768

Purchased intangible assets

-

-

-

-

-

-

-

-

-

-

-

11,357